Galmed Pharmaceuticals (NASDAQ: GLMD) granted new deadline to meet $1 bid rule
Rhea-AI Filing Summary
Galmed Pharmaceuticals Ltd. reports that Nasdaq has granted an additional 180 calendar days, until January 25, 2027, for the company to regain compliance with Nasdaq’s minimum $1 bid price per share requirement.
Galmed was first notified on January 29, 2026 that its ordinary shares had traded below $1 for 30 consecutive trading days and did not regain compliance by the initial July 28, 2026 deadline. The company requested and received the extended period. Compliance will be restored if the bid price closes at or above $1 per share for at least 10 consecutive trading days before January 25, 2027. This report is incorporated by reference into Galmed’s existing Form S-8 and Form F-3 registration statements.
Positive
- None.
Negative
- Non-compliance with Nasdaq $1 bid requirement persists after the initial deadline, indicating the company’s shares have traded below $1 for an extended period and remain subject to Nasdaq’s continued listing standards process.
Key Figures
Extended compliance deadline: January 25, 2027
Minimum bid price: $1 per share
Initial notice date: January 29, 2026
+3 more
6 metrics
Extended compliance deadline
January 25, 2027
New Nasdaq deadline to regain $1 minimum bid price compliance
Minimum bid price
$1 per share
Nasdaq Listing Rule 5550(a)(2) requirement for ordinary shares
Initial notice date
January 29, 2026
Date Nasdaq first notified Galmed of bid price deficiency
Initial compliance period end
July 28, 2026
End of first 180-day period to cure bid price deficiency
Trading day requirement
10 consecutive trading days
Period the bid must close at or above $1 to regain compliance
Initial non-compliance window
30 consecutive trading days
Duration shares traded below $1 before first Nasdaq notice
Key Terms
Nasdaq Listing Rule 5550(a)(2), minimum $1 bid price per share requirement, Registration Statements on Form S-8, Registration Statements on Form F-3
4 terms
Nasdaq Listing Rule 5550(a)(2) regulatory
"under Nasdaq Listing Rule 5550(a)(2) on January 29, 2026"
Registration Statements on Form S-8 regulatory
"incorporated by reference into the Company’s Registration Statements on Form S-8"
Registration Statements on Form F-3 regulatory
"and the Company’s Registration Statements on Form F-3"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Galmed Pharmaceuticals (GLMD) disclose in its July 2026 Form 6-K?
Galmed disclosed that Nasdaq granted an additional 180 days, until January 25, 2027, for it to regain compliance with the $1 minimum bid price requirement for its ordinary shares after failing to do so by July 28, 2026.
What is the new Nasdaq compliance deadline for GLMD’s $1 minimum bid price?
Nasdaq set January 25, 2027 as Galmed’s new deadline to cure its bid price deficiency. This follows an earlier period ending July 28, 2026, during which the company did not regain compliance with the $1 per share minimum.
How can Galmed Pharmaceuticals (GLMD) regain compliance with Nasdaq’s bid price rule?
Galmed will regain compliance if its ordinary shares’ bid price closes at or above $1 per share for at least 10 consecutive trading days at any time before January 25, 2027, under Nasdaq’s listing rules.
When did Nasdaq first notify GLMD about its minimum bid price deficiency?
Nasdaq first notified Galmed on January 29, 2026 that its ordinary shares failed to meet the $1 minimum bid price requirement after trading below that level for 30 consecutive trading days under Nasdaq Listing Rule 5550(a)(2).
Which registration statements does this GLMD Form 6-K affect?
The report is incorporated by reference into Galmed’s Registration Statements on Form S-8 (including Nos. 333-206292 and 333-227441) and Form F-3 (including Nos. 333-272722 and 333-283241), making the update part of those filings.